Revenue

3 Months Ended

Mar. 31, 2022

Segment Reporting [Abstract]

Revenue

Revenue

Disaggregation of Revenue by Product

MIMEDX has two primary classes of products: (1) Advanced Wound Care, or Section 361, products, consisting of its tissue and cord sheet allograft products, and (2) Section 351 Products, consisting of the Company’s micronized and particulate products. Advanced Wound Care is further disaggregated between the Company’s Tissue/Other and Cord products.

Below is a summary of net sales by each class of product (in thousands):

	Three Months Ended March 31,
	2022		2021
Advanced Wound Care
Tissue/Other	$	52,852	$	46,569
Cord	5,597		4,960
Total Advanced Wound Care	58,449		51,529
Section 351	377		8,140
Other(1)	68		298
Net sales	$	58,894	$	59,967

(1) “Other” represents revenue transactions in the indicated period relating to performance obligations settled prior to October 1, 2019, the date at which the Company changed its pattern of revenue recognition. For all practical purposes, the Company is not able to allocate these revenue transactions to different product groups.

Disaggregation of Revenue by Customer

MIMEDX has two primary distribution channels: (1) direct to customers (healthcare professionals and/or facilities) (“Direct Customers”), and (2) sales through distributors (“Distributors”).

Below is a summary of net sales by each customer type (in thousands):

	Three Months Ended March 31,
	2022		2021
Direct Customers	$	57,473	$	57,555
Distributors	1,421		2,412
Net sales	$	58,894	$	59,967

The Company did not have significant foreign operations or a single external customer from which 10% or more of revenues were derived during the three months ended March 31, 2022 or 2021.